DEC 1 2 2007

PTO/SB/08a (11-07) Approved for use through 11/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

fe required to respond to a collection of information unless it contains a valid OMR control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Substitute for form 1449A/PTO

1 Sheet

(Use as many sheets as necessary)

1995 no r...

1995 no Person

00	ompiete if Known	'	
Application Number	10/539,208		
Filing Date	MAY 24, 2006		
First Named Inventor	DAVID RAAB		
Art Unit	1644		
Examiner Name	NOT YET ASSIGNED		
Attorney Docket Number	B&B-135		

U. S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	1	us- 2002/0072864A1	06/13/2002	LACROIX et al.				
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						
		US-						

		FOREIGN I	PATENT DOC	UMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	₹8
	2	WO 98/34640	08/13/1998	MERCK & CO., INC.		
	3	WO 00/42560	07/20/2000	MAXYGEN, INC.		
	4	DE 199 14 808 A1	10/19/2000	RAUHE, HILMAR		
	5	WO 01/16810 A2	03/08/2001	THE EUROPEAN MOLECULAR BIOLOGY LAB.		
	6	EP 1 156 112 A1	11/21/2001	GENEART GMBH		

Examiner Signature	/Shubo Zhou/	Date Considered	06/21/2010

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered include copy of this form with next communication to applicant. "Applicant's unique citation designation number (optional). "See Nicco Godes of USPTO Patent Documents at https://www.uspto.oper.org/ org/https://www.uspto.oper.org/https://www.uspto.oper.org/https://www.uspto.oper.org/https://www.uspto.oper.org/ org/https://www.uspto.oper.org/https://www.uspto.oper.org/https://www.uspto.oper.org/https://www.uspto.oper.org/https://www.uspto.oper.org/https://www.uspto.oper.org/https://www.uspto.oper.org/https://www.uspto.oper.org/<a href="https://www.uspto.ope Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 123 and 37 CPR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Officer, U.S. Department of Commerce, P.O. Box 1459, Alexandria, VA 22313-1450, D.O. NOT SEND FEES OR COMPLETED SCRING TO THIS COMPLETED SCRING TO THE SCRING TO THIS COMPLETED SCRING TO THE SCRING TO THE SCRING TO THE SCRING TO THIS COMPLETED SCRING TO THE SCRING ADDRESS. SEND TO Commissioner for Patents. B.O. Box 1450 Alexandria V 22313-1450 WHERE LINE American Legislet, Inc. ALL REFERENCES CONSIDERED EXCEPTS WHERE LINE WITH THE PROPERTY OF THE PROP

Approved for use through 11/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known 10/539.208 Application Number MAY 24, 2006 Filing Date DAVID RAAB First Named Inventor Art Unit 1644 Examiner Name NOT YET ASSIGNED Attorney Docket Number B&B-135

(Use as many sheets as necessary) 2 Sheet

			U. S. PATENT D		
Examiner Initials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
	+	Number-Kind Code ² (f known)			Figures Appear
		US-			
	П	US-			
		US-			

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ "Number ⁴ "Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶	
	7	WO 02/29088 A2	04/112002	TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA			
	F						
	ļ					_	

_			 	
	xaminer Signature	/Shubo Zhou/	Date Considered	06/21/2010

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 603. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. "Applicant's unique citation designation number (optional). "See Mincs Codes of USPTO Patient Documents at https://www.sestgo.opy of MPEP 901-04. "Either Observation document, by the two-letter code (WIPO Standard ST.3)." For Japanese patient documents, the indication of the year of the reign of the Emperor must procede the serial number of the parent document. "Yard of document by the appropriate symbols as indicated on the document union's WIPO Standard ST.16 if possible." Applicant is to place a check mark here it English language. Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissione for Patents, P.O. Box 1550 Alexandria, VA 2231 3-1450.

ALL REFERENCES CONSIDERED EXCEPTS WHERE LINED WHAT PARENCE AND ADDRESS. SEND TO: Commissione for Patents Provided H.

Approved for use through 11/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number Complete if Known Substitute for form 1449B/PTO Application Number 10/539.208 INFORMATION DISCLOSURE Filing Date MAY 24, 2006 STATEMENT BY APPLICANT First Named Inventor DAVID RAAB Art Unit 1644 (Use as many sheets as necessary) Examiner Name NOT YET ASSIGNED Attorney Docket Number Sheet 13 B&B-135 4

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), tille of the article (when appropriate), tille of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		HOOVER DAVID M ET AL: "DNAWorks: an automated method for designing	
		oligonucleotides for PCR-based gene synthesis" NUCLEIC ACIDS RESEARCH, OXFORD	
	8	UNIVERSITY PRESS, SURREY, GB, Bd, 30, Nr. 10, 15, Mai 2002 (2002-05-15).	
		CHRISLAINE WITHERS-MARTINEZ ET AL: "PCR-based gene synthesis as an efficient	
		approach for expression of the A+T-rich malaria genome" PROTEIN ENGINEERING,	
	9	OXFORD UNIVERSITY PRESS, SURREY, GB, Bd. 12, Nr. 12, December 1999 (1999-12).	_
		WILLIAMS D P ET AL: "DESIGN, SYNTHESIS AND EXPRESSION OF A HUMAN	
	10	INTERLEUKIN-2 GENE INCORPORATING THE CONDON USAGE BIAS FOUND IN	
	10	HIGHLY EXPRESSED ESCHERICHIA COLI GENES" NUCLEIC ACIDS RESEARCH.	
		OXFORD UNIVERSITY PRESS, SURREY, GB, Bd. 16, Nr. 22, 25 November 1988 (1988-11-25).	
	†	LEE F ET AL: "ISOLATION OF COMPLEMENTARY DNA FOR A HUMAN	
	1	GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR BY FUNCTIONAL	
	11	EXPRESSION IN MAMMALIAN CELLS" PROCEEDINGS OF THE NATIONAL ACADEMY	
	1		
		OF SCIENCES OF THE UNITED STATES OF AMERICA, Bd. 82, Nr. 13, 1985.	
		MEAZZA R ET AL: "Identification of a novel interleukin-15 (IL-15) transcript isoform	
		generated by alternative splicing in human small cell lung cancer cell lines." ONCOGENE.	
	12	16 MAY 1996, Bd. 12, Nr. 10, 16, Mai 1996 (1996-05-16).	
		SINCLAIR, G. & CHOY, F.Y.: Synonymous codon usage bias and the expression of human	
		glucocerebrosidase in the methylotrophic yeast, Pichia pastoris. Protein Expr. Purif.	
	13	(October 2002) 26 (1) 96-105.	
		L	
	١	HAMDAN, F.F. et al.: Codon optimization improves heterologous expression of a	
	14	Schistosoma mansoni cDNA in HEK293 cells. Parasitol. Res. (June 2002) 88 (6) 583-6.	ļ
		DEML, L. et al.: Multiple effects of codon usage optimization on expression and	
	l	immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus	
	15	type 1 Gag protein. J. Virol. (2001) 75 (22) 10991-1001	l

Examiner Signature	/Shube Zhou/	Date Considered	. 06/21/2010

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.
¹ Applicants unique citation designation number (optional).
² Applicants unique citation designation number (optional).
³ Applicants unique citation designation number (optional).
⁴ Applicants unique citation designation number (optional).
⁴ Applicants to produce the first produce the citation of the citation o

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

This collection of information is all winest by 18° CF1 197 in 158. This information is required to detain or settin a benefit by the public which is the figure of the CF1 197 in 158. This information is required to detain or settin a benefit by the public which is the figure of the CF1 197 in 158. This information is required to detain or settin a benefit by the public which is the first of the CF1 197 in 158. This information is the confidence of the CF1 197 in 158. This collection is estimated to take 2 benefit including gathering, preparing, and submitting the completed application from to the USPTO Time will vary depending upon the individual case. Any comment on the amount of the purp currective to complete his form androw suppositions for enabling this burdon, should be sent to the CF1 information CF1. Set petern and Trademark Office, U.S. Department of Commerce, P.O. Box 1459, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissionner for Patents, P.O. Box 1459, Alexandria, VA 22313-1450.

PTO/SB/08b (11-07)

Approved for use through 11/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Apt of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Subst	itute for form 1449B/PTO				Complete if Known	
				Application Number	10/539,208	
INF	ORMATION DIS	CLOS	URE	Filing Date	MAY 24, 2006	
STATEMENT BY APPLICANT				First Named Inventor	DAVID RAAB	
				Art Unit	1644	
(Use as many sheets as necessary)				Examiner Name	NOT YET ASSIGNED	
Sheet	4	of	4	Attorney Docket Number	B&B-135	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposlum, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T°		
	16	HALE, R.S. & THOMPSON, G.: Codon optimization of the gene encoding a domain from human type 1 neurofibromin protein results in a threefold improvement in expression level in Escherichia coli, Protein Expr. Purif. (1998) 12 (2) 185-8.			
	17	HUMPHREVS, D.P. et al.: High-level periplasmic expression in Escherichia coll using a eukaryotic signal peptide: importance of codon usage at the 5' end of the coding sequence. Protein Expr. Purif. (2000) 20 (2) 252-64			
	18	KIM, C.H. et al.: Codon optimization for high-level expression of human erythropoietin (EPO) in mammalian cells. Gene (1977) 199 (1-2) 293-301			

Examiner Signature	/Shubo Zhou/	Date Considered	06/21/2010

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

considered. Include copy of this form with next communication to applicant.

*Applicant's unique diation designation number (optional) **Explicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CPR 1,97 and 1,98. The information is enquired to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.